SCHEMBL6151268

SCHEMBL6151268

CC(=O)c1cc(NC(=O)CCC(N)=O)cc(C(C)=O)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FURIN P09958 6/20 0.50
F10 P00742 1/20 0.48
KMT2A Q03164 3/20 0.47
PARP1 P09874 1/20 0.46
PARP10 Q53GL7 1/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
TP53 P04637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MEN1 O00255 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 2/20 0.43
F2 P00734 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6150719 0.92 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL5973945 0.92 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL5974301 0.91 KMT2A (0.53) FURINF10KMT2AALDH1A1MAPT
SCHEMBL5973917 0.90 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL6149232 0.90 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL5442050 0.90 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL8445590 0.90 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL8446705 0.90 FURIN (0.56) FURINF10KMT2APARP1PARP10
SCHEMBL27674139 0.85 KMT2A (0.64) KMT2APARP1PARP10ALDH1A1MAPT
SCHEMBL5974764 0.84 HDAC3 (0.54) FURINF10KMT2APARP1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004016258-A1 THERAPEUTICAL USE OF GUANYLHYDRAZONES FOR TREATING DISEASES ASSOCIATED WITH DENDRITIC CELL MATURATION MONDOBIOTECH LABORATORIES ANSTALT (CH) 2004-02-26 WO claimed
US-20030203969-A1 Pharmaceutically active aromatic guanylhydrazones AXXIMA PHARMACEUTICALS AG (DE) 2003-10-30 US claimed
WO-2003006426-A1 AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES AXXIMA PHARMACEUTICALS AG (DE) 2003-01-23 WO claimed
EP-1255541-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES Axxima Pharmaceuticals Aktiengesellschaft (DE) 2002-11-13 EP claimed
WO-2002000613-A2 INHIBITORS OF HEPATITIS B VIRUS INFECTION AXXIMA PHARMACEUTICALS AG (DE) 2002-01-03 WO claimed
WO-2001056553-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES AXXIMA PHARMACEUTICALS AG (DE) 2001-08-09 WO claimed
EP-1255541-B1 AROMATIC GUANYLHYDRAZONE FOR THE TREATMENT OF RESISTANT VIRAL INFECTIONS BEVEC DORIAN (DE) 2005-11-09 EP disclosed
WO-2004016258-A1 THERAPEUTICAL USE OF GUANYLHYDRAZONES FOR TREATING DISEASES ASSOCIATED WITH DENDRITIC CELL MATURATION MONDOBIOTECH LABORATORIES ANSTALT (CH) 2004-02-26 WO disclosed
EP-1389480-A1 Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation Mondobiotech Interferon SA (CH) 2004-02-18 EP disclosed
US-20030203969-A1 Pharmaceutically active aromatic guanylhydrazones AXXIMA PHARMACEUTICALS AG (DE) 2003-10-30 US disclosed
WO-2003006426-A1 AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES AXXIMA PHARMACEUTICALS AG (DE) 2003-01-23 WO disclosed
CN-1098070-C Guanylhydrazones for treating inflammatory conditions PICOWER INST MED RES (US) 2003-01-08 CN disclosed
EP-1255541-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES Axxima Pharmaceuticals Aktiengesellschaft (DE) 2002-11-13 EP disclosed
WO-2002000613-A2 INHIBITORS OF HEPATITIS B VIRUS INFECTION AXXIMA PHARMACEUTICALS AG (DE) 2002-01-03 WO disclosed
WO-2001056553-A2 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES AXXIMA PHARMACEUTICALS AG (DE) 2001-08-09 WO disclosed
EP-0746312-A4 GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS PICOWER INST MED RES (US) 1999-05-26 EP disclosed
US-5849794-A Guanylhydrazones and their use to treat inflammatory conditions THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) 1998-12-15 US disclosed
CN-1144480-A Guanylhydrazones for treating inflammatory conditions PICOWER INST MED RES (US) 1997-03-05 CN disclosed
EP-0746312-A1 GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) 1996-12-11 EP disclosed
WO-1995019767-A1 GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) 1995-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203969-A1 Pharmaceutically active aromatic guanylhydrazones DHPS, GGPS1, GMPS FURIN 2883/4885F10 3183/4885KMT2A 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.